Dr Andreas Schmidt is a serial entrepreneur and successful biotech CEO. Following the recent acquisition of his startup Proteona by Singleron Biotechnologies he is currently heading the global business development with an emphasis on clinical and pharma collaborations enabling single cell and multi-omic precision medicine. Previously he has co-founded the venture capital backed proteomics company AYOXXA Biosystems. Dr Schmidt serves as board member, advisor and share holder of several biotech companies and investment funds centered in Asia, Europe and North America. His engagements are focussed on new approaches to precision medicine, multi-omics platforms, cell therapy and artificial intelligence enabled clinical research.